Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Omada Health
OMDA
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $1.3B
$22.39
▼ -1.02%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$10.28 - $26.92
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 25.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Clinically validated programs with peer-reviewed evidence of efficacy and ROI
- Integrated platform combining digital coaching, AI-driven personalization, and clinical oversight
- Established relationships with major health plans and employers covering millions of lives
- Proprietary data and outcomes tracking enabling continuous program optimization
Bear Case
2 risks
- High volatility (beta 2.1). Larger-than-normal price swings expected.
- Growth premium of 10.6x vs Healthcare IT & Services peers. Significant premium - requires sustained high growth to justify.
Growth
Turning profitable
Expanding adoption of virtual care and digital health solutions post-pandemic
Value
Growth premium of 10.6x vs Healthcare IT & Services peers. Significant premium - requires sustained high growth to justify.
Momentum
Hot
+79.8% over 3m
Quality
Excellent
High-growth business (49% revenue growth, 66% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying OMDA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 6, 2026
MAY 7, 2026
Reported EPS of -$0.05 vs -$0.13 consensus (+60.8% surprise). Revenue of $78.0M vs $74.1M expected (+5.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+60.8%
Next: Aug 6, 2026
Revenue trend · last 8Q
—
—
+47%
+57%
+49%
+49%
+58%
+42%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$41.2M
$45.5M
$48.0M
$55.0M
$61.4M
$68.0M
$75.8M
$78.0M
Margins · last 8Q
Gross
—
Operating
—
Profit
-3.8%
Wall Street consensus
10 analysts · 90% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
90%
Hold
10%
Sell
0%
Median Price Target
$19.00
▼ -15.1% vs $22.39
Latest: Morgan Stanley · Jun 22, 2026
3 analysts covering